Contact PI/Project LeaderNAGARKATTI, PRAKASH S Other PIs
Awardee OrganizationUNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
Description
Abstract Text
The environmental sensor, aryl hydrocarbon receptor (AhR) serves as a ligand for pollutants as well as
for plant, microbial and endogenous compounds. Following AhR ligation, the activated AhR regulates gene
expression through the binding of AhR/ARNT complex to specific DNA motifs known as Dioxin Response
Elements (DREs). Studies from our lab and elsewhere have shown that some AhR ligands have potent
immunosuppressive properties. Inflammatory bowel disease (IBD) results from chronic inflammation in the
gastrointestinal tract that affects 1.5 million people in the US. The pathogenesis of IBD involves complex
interactions between gut microbiota, immune response, environmental and dietary factors, and
genetic/epigenetic regulation. Recently, we made an exciting observation that the AhR ligand and plant product,
I3C ameliorates colitis in mice, which was associated with anti-inflammatory effects, regulation of gut dysbiosis,
and enhanced expression of β-defensins (mBD1,2,3) by Colonic Epithelial Cells (CEC). β-defensins constitute
antimicrobial peptides (AMPs) that resist microbial colonization of epithelial surfaces in the colonic tissue. β-
defensins may also mediate anti-inflammatory effects. In fact, studies have shown defective expression of
intestinal AMPs particularly defensins in IBD patients. We were excited to uncover DREs in the promoters of
mouse β-defensins (mBD1, 2, and 3). In the current study, we will test the central hypothesis that dietary indoles
(I3C) attenuate colitis through AhR activation leading to increased expression of mBDs by CECs via pathways
involving DREs, and/or epigenetic regulation resulting in modulation of microbiota and prevention of epithelial
barrier damage. Furthermore, we propose that mBDs induced by I3C play a critical role in restoring healthy gut
microbiota, preventing intestinal barrier damage and suppressing colonic inflammation through induction of
Tregs. Aim 1 will test the mechanisms of mBD induction by dietary indoles. We will use reporter assay, promoter
bashing and electrophoretic mobility shift assay to determine whether I3C activated AhR directly binds to the
DREs to induce mBDs. We will also determine the effect of I3C on the mBD expression by using AhR cKO mice
with AhR deletion in IEC, ILC3 and Tregs. In Aim 2, we will study epigenetic regulation of β-defensins by dietary
indoles. To that end, we will test whether I3C regulates mBD expression by altering histone modification and
decreasing DNA methylation. We will specifically determine if I3C regulates the SATB1-mediated histone
deacetylation and chromatin remodeling. In Aim 3, we will test whether administration of mBDs offers protection
from colitis by regulating gut dysbiosis, preventing CEC barrier damage, enhancing Treg subsets and decreasing
Th17 subpopulations to attenuate colonic inflammation. Finally, we will use mBD KO mice to test whether mBDs
are required for I3C-mediated protection from colitis. The proposed studies are highly significant because they
will identify novel mechanisms through which dietary indoles suppress colitis by altering the microbiota, through
activation of AhR leading to increased expression of host-derived AMPs, specifically β-defensins.
Public Health Relevance Statement
Environmental pollutants as well as plant, microbial and host-derived products can bind to aryl hydrocarbon
receptors (AhR). Our studies will determine how dietary indoles bind to AhR and then elements in the DNA to
produce anti-microbial peptides. These peptides can cause changes in gut microbiota and immunosuppression.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
041387846
UEI
J22LNTMEDP73
Project Start Date
27-September-2021
Project End Date
31-August-2026
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$53,717
Direct Costs
$39,439
Indirect Costs
$14,278
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$53,717
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R01AI160896-04S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01AI160896-04S1
Patents
No Patents information available for 3R01AI160896-04S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01AI160896-04S1
Clinical Studies
No Clinical Studies information available for 3R01AI160896-04S1
News and More
Related News Releases
No news release information available for 3R01AI160896-04S1
History
No Historical information available for 3R01AI160896-04S1
Similar Projects
No Similar Projects information available for 3R01AI160896-04S1